Scarica l'app Stockscreener
7.17
5.91%
-0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$7.62
Aprire:
$7.5
Volume 24 ore:
1.24M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.07B
Reddito:
$177.28M
Utile/perdita netta:
$-195.24M
Rapporto P/E:
-5.3507
EPS:
-1.34
Flusso di cassa netto:
$-114.54M
1 W Prestazione:
-7.72%
1M Prestazione:
-15.85%
6M Prestazione:
+55.53%
1 anno Prestazione:
+110.26%
Intervallo 1D:
$6.96
$7.58
Intervallo di 1 settimana:
$6.255
$7.92
Portata 52W:
$2.28
$8.95
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Confronta ADPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.17 | 1.07B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada
Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com
Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com
Adaptive Biotechnologies director sells shares worth $402,270 By Investing.com - Investing.com UK
Adaptive Biotechnologies Executives Sell Shares - TradingView
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - The Manila Times
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World
Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CFO sells shares worth $72,072 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies chief people officer sells $145,845 in stock - Investing.com
Adaptive Biotechnologies chief people officer sells $145,845 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies director sells $124,372 in stock - Investing.com India
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock - Investing.com India
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock - Investing.com
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock - Investing.com
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock - Investing.com
Private Advisor Group LLC Makes New $264,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Increased by Rhumbline Advisers - Defense World
D.A. Davidson & CO. Buys 6,725 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies’ (ADPT) “Overweight” Rating Reiterated at Piper Sandler - Defense World
Cathie Wood’s Ark Invest Makes Bold Moves: Buys BEAM & NU, Sells MELI & ADPT - Apna Kal
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive BiotechnologiesARK Fintech Innovation ETF (ARCA:ARKF), Adaptive Biotechnologies (NASDAQ:ADPT) - Benzinga
Adaptive Biotechnologies CEO Chad Robins sells over $2.4m in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CEO Chad Robins sells over $2.4m in stock - Investing.com Canada
Cathie Wood’s ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com India
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock By Investing.com - Investing.com Australia
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com
Adaptive Biotechnologies CEO Chad Robins sells $3.99 million in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CEO Chad Robins sells $3.99 million in shares - Investing.com India
Adaptive Biotechnologies CEO Chad M Robins Sells Over $3.9 Million in Company Stock - TradingView
ADPT stock soars to 52-week high, reaching $8.33 - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% Following Analyst Upgrade - Armenian Reporter
Scotiabank Forecasts Strong Price Appreciation for Adaptive Biotechnologies (NASDAQ:ADPT) Stock - Defense World
Legato Capital Management LLC Decreases Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% on Analyst Upgrade - MarketBeat
Scotiabank Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price - MarketBeat
Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank - Yahoo Finance
Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements - MSN
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 5.2%Time to Sell? - MarketBeat
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2024 Earnings Call Transcript - Insider Monkey
ADPT stock soars to 52-week high, reaching $8.33 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):